[HTML][HTML] Comparative Effectiveness and Safety of Direct Oral Anticoagulants in Low Body Weight Patients with Atrial Fibrillation: A Systematic Review and Meta …
MN Elshafei, M Salem, A El-Bardissy… - … Drugs and Therapy, 2024 - Springer
Introduction Direct oral anticoagulant (DOAC) agents are established as the anticoagulation
strategy of choice for a variety of clinical risks. Despite this, uncertainty still exists with regard …
strategy of choice for a variety of clinical risks. Despite this, uncertainty still exists with regard …
Efficacy and Safety of Low‐Dose Edoxaban by Body Weight in Very Elderly Patients With Atrial Fibrillation: A Subanalysis of the Randomized ELDERCARE‐AF Trial
M Akao, T Yamashita, M Fukuzawa… - Journal of the …, 2024 - Am Heart Assoc
Background The ELDERCARE‐AF trial showed that low‐dose edoxaban benefits elderly
patients with nonvalvular atrial fibrillation considered ineligible for standard oral …
patients with nonvalvular atrial fibrillation considered ineligible for standard oral …
Effectiveness and safety of reduced and standard daily doses of direct oral anticoagulants in patients with nonvalvular atrial fibrillation: A cohort study using national …
K Kubota, N Ooba - Clinical Epidemiology, 2022 - Taylor & Francis
Purpose To compare the effectiveness and safety of reduced or standard daily doses of
direct oral anticoagulants (DOACs) with warfarin in Japanese patients with nonvalvular atrial …
direct oral anticoagulants (DOACs) with warfarin in Japanese patients with nonvalvular atrial …
[HTML][HTML] Evaluation of Apixaban standard dosing in underweight patients with non-valvular atrial fibrillation: a retrospective cohort study
Background Recent guidelines recommend using direct oral anticoagulants (DOACs) as first-
line agents in patients with non-valvular atrial fibrillation (NVAF). Research is currently …
line agents in patients with non-valvular atrial fibrillation (NVAF). Research is currently …